If you liked this article you might like

Hep C Business Slow-Down Could Hamper Bristol-Myers' Future
5 Blue-Chip Breakouts to Buy This Summer
Buy Gilead Sciences While It's Wallowing
Jim Cramer's 'Mad Money' Recap: 'Good Enough' Is a Triumph